| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Jun, 2023 | Jun, 2022 | Mar, 2026 |
| Sales | 18,417 | 13,009 | 7,236 | 4,113 | 0 |
| Sales Growth | +41.57% | +79.79% | +75.92% | unch | unch |
| Net Income | 215 | -1,670 | -3,079 | -4,541 | 0 |
| Net Income Growth | +112.85% | +45.75% | +32.20% | unch | unch |
Biome Australia Ltd (BIO.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals vitamins and weight management products and live biotherapeutics. The company has one operating segment: researching, developing, manufacturing and distributing evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
Fiscal Year End Date: 06/30